nisoldipine has been researched along with Diabetes Mellitus, Type 2 in 19 studies
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Analysis of the 470 patients in the trial who had hypertension (base-line diastolic blood pressure, > or = 90 mm Hg) showed similar control of blood pressure, blood glucose and lipid concentrations, and smoking behavior in the nisoldipine group (237 patients) and the enalapril group (233 patients) throughout five years of follow-up." | 9.08 | The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. ( Biggerstaff, SL; Estacio, RO; Gifford, N; Hiatt, WR; Jeffers, BW; Schrier, RW, 1998) |
| "Nisoldipine (N) is a dihydropyridine calcium antagonist marketed as a racemic mixture and used for the treatment of hypertension." | 5.10 | Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. ( Coelho, EB; Dos Santos, NA; Geleilete, TJ; Lanchote, VL; Marques, MP, 2002) |
| "3 years of follow-up of 470 patients with hypertension and evaluates the effects of intensive and moderate blood pressure therapy using nisoldipine versus enalapril as the initial antihypertensive medication for nephropathy, retinopathy, and neuropathy." | 5.09 | Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. ( Estacio, RO; Gifford, N; Jeffers, BW; Schrier, RW, 2000) |
| "Analysis of the 470 patients in the trial who had hypertension (base-line diastolic blood pressure, > or = 90 mm Hg) showed similar control of blood pressure, blood glucose and lipid concentrations, and smoking behavior in the nisoldipine group (237 patients) and the enalapril group (233 patients) throughout five years of follow-up." | 5.08 | The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. ( Biggerstaff, SL; Estacio, RO; Gifford, N; Hiatt, WR; Jeffers, BW; Schrier, RW, 1998) |
| "Nisoldipine treatment in vitro significantly decreased [Ca2+]i, and significantly improved RBC-df." | 1.30 | Nisoldipine improves the impaired erythrocyte deformability correlating with elevated intracellular free calcium-ion concentration and poor glycaemic control in NIDDM. ( Adachi, T; Fujimoto, S; Fujita, J; Hamamoto, Y; Kajikawa, M; Mizuno, N; Mukai, E; Nishimura, M; Seino, Y; Takeda, T; Tsuda, K; Yu, L, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (63.16) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chonchol, M | 1 |
| Dale, R | 1 |
| Schrier, RW | 10 |
| Estacio, R | 2 |
| Marques, MP | 1 |
| Coelho, EB | 1 |
| Dos Santos, NA | 1 |
| Geleilete, TJ | 1 |
| Lanchote, VL | 1 |
| Mehler, PS | 2 |
| Coll, JR | 1 |
| Esler, A | 3 |
| Hiatt, WR | 2 |
| Havranek, EP | 1 |
| Estacio, RO | 8 |
| Savage, S | 1 |
| Johnson Nagel, N | 1 |
| Feig, PU | 1 |
| MacCarthy, EP | 1 |
| Lukken, NJ | 1 |
| Ziegler, R | 1 |
| Jeffers, B | 1 |
| Fujita, J | 2 |
| Tsuda, K | 2 |
| Obayashi, H | 1 |
| Fukui, I | 1 |
| Ishida, H | 1 |
| Seino, Y | 2 |
| Jeffers, BW | 2 |
| Biggerstaff, SL | 1 |
| Gifford, N | 2 |
| Cutler, JA | 1 |
| Osende, JI | 1 |
| Walker, AM | 1 |
| Molitch, ME | 1 |
| Pahor, M | 1 |
| Tatti, P | 1 |
| Takeda, T | 1 |
| Yu, L | 1 |
| Fujimoto, S | 1 |
| Kajikawa, M | 1 |
| Nishimura, M | 1 |
| Mizuno, N | 1 |
| Hamamoto, Y | 1 |
| Mukai, E | 1 |
| Adachi, T | 1 |
| Mehler, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 trials available for nisoldipine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Serum phosphorus and cardiovascular mortality in type 2 diabetes.
Topics: Antihypertensive Agents; Calcium; Cardiovascular Diseases; Cohort Studies; Comorbidity; Diabetes Mel | 2009 |
Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus.
Topics: Adult; Antihypertensive Agents; Area Under Curve; Biomarkers; Blood Glucose; Blood Pressure; Cross-O | 2002 |
Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cohort Studies; Comorbidity; Death | 2003 |
Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, T | 2003 |
The ABCD (Appropriate Blood Pressure Control in Diabetes) trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Enalapril; Female | 1993 |
Appropriate Blood Pressure Control in NIDDM (ABCD) Trial.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel | 1996 |
The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Dise | 1998 |
Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Cha | 1998 |
The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) and combination therapies.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Ty | 2000 |
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes | 2002 |
8 other studies available for nisoldipine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Nisoldipine blocks the increase of intracellular free calcium-ion concentration associated with elevated sodium-lithium countertransport activity in erythrocytes in patients with NIDDM.
Topics: Adult; Antiporters; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Erythrocytes; Fema | 1997 |
Calcium-channel blockers for hypertension--uncertainty continues.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Diseases; Diabete | 1998 |
Calcium blockers questioned.
Topics: Calcium Channel Blockers; Diabetes Mellitus, Type 2; Humans; Hypertension; Myocardial Infarction; Ni | 1998 |
Nisoldipine and myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Enala | 1998 |
Nisoldipine and myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Enala | 1998 |
Nisoldipine and myocardial infarction.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diabetes Mellitus, | 1998 |
Nisoldipine improves the impaired erythrocyte deformability correlating with elevated intracellular free calcium-ion concentration and poor glycaemic control in NIDDM.
Topics: Adult; Blood Glucose; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Erythrocyte Defo | 1999 |
Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Diseases; Diabete | 2000 |